Localization and role of metabotropic glutamate receptors subtype 5 in the gastrointestinal tract

Andrea Ferrigno, Clarissa Berardo, Laura G Di Pasqua, Veronica Siciliano, Plinio Richelmi, Mariapia Vairetti

Andrea Ferrigno, Clarissa Berardo, Laura G Di Pasqua, Veronica Siciliano, Plinio Richelmi, Mariapia Vairetti, Department of Internal Medicine and Therapeutics (Cellular and Molecular Pharmacology and Toxicology), University of Pavia, 27100 Pavia, Italy

Author contributions: Ferrigno A contributed to data acquisition, data interpretation, composition of the draft and approval of the final version; Berardo C, Di Pasqua LG and Siciliano V contributed to data acquisition, critical revision and approval of the final version; Richelmi P contributed to data interpretation, critical revision and approval of the final version; Vairetti M contributed to conception of the study, design of the study, data interpretation, critical revision and approval of the final version.

Supported by Italian ministry of University, Research and Instruction.

Conflict-of-interest statement: Ferrigno A, Berardo C, Di Pasqua LG, Siciliano V, Richelmi P and Vairetti M declare no conflict of interest related to this publication.

Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

Manuscript source: Invited manuscript

Received: February 4, 2017  Peer-review started: February 5, 2017  First decision: April 26, 2017  Revised: May 3, 2017  Accepted: June 19, 2017  Article in press: June 19, 2017  Published online: July 7, 2017

Abstract

Metabotropic glutamate receptor subtype 5 (mGluR5) is a Group I mGlu subfamily of receptors coupled to the inositol trisphosphate/diacylglycerol pathway. Like other mGluR subtypes, mGluR5s contain a phylogenetically conserved, extracellular orthosteric binding site and a more variable allosteric binding site, located on the heptahelical transmembrane domain. The mGluR5 receptor has proved to be a key pharmacological target in conditions affecting the central nervous system (CNS) but its presence outside the CNS underscores its potential role in pathologies affecting peripheral organs such as the gastrointestinal (GI) tract and accessory digestive organs such as the tongue, liver and pancreas. Following identification of mGluR5s in the mouth, various studies have subsequently demonstrated its involvement in mechanical allodynia, inflammation, pain and oral cancer. mGluR5 expression has also been identified in gastrointestinal vagal pathways. Indeed, experimental and human studies have demonstrated that mGluR5 blockade reduces transient lower sphincter relaxation and reflux episodes. In the intestine, mGluR5s have been shown to be involved in the control of intestinal inflammation, visceral pain and the epithelial barrier function. In the liver, mGluR5s have a permissive role in the onset of ischemic injury in rat and mice hepatocytes. Conversely, livers from mice treated with selective negative allosteric modulators...
and mGluR5 knockout mice are protected against ischemic injury. Similar results have been observed in experimental models of free-radical injury and in vivo mouse models of acetaminophen intoxication. Finally, mGluR5s in the pancreas are associated with insulin secretion control. The picture is, however, far from complete as the review attempts to establish in particular as regards identifying specific targets and innovative therapeutic approaches for the treatment of GI disorders.

Key words: Metabotropic glutamate receptor subtype 5; Esophagus; Intestine; Liver; Pancreas

© The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.

Core tip: Metabotropic glutamate 5 receptors (mGluR5s) belong to Group I mGlu receptors which are coupled to the inositol trisphosphate/diacylglycerol pathway. As well as in the brain, mGluR5s and their ligands have been found in peripheral organs, including those associated with the gastrointestinal (GI) tract. We review published findings about their identification and role in the mouth, esophagus, stomach and intestine and accessory digestive organs such as the tongue, liver and pancreas. We conclude that mGluR5s are still poorly studied in the GI tract and their peripheral non-synaptic signaling, and that their therapeutic potential needs to be further investigated.

Ferrigno A, Berardo C, Di Pasqua LG, Siciliano V, Richelmi P, Vairetti M. Localization and role of metabotropic glutamate receptors subtype 5 in the gastrointestinal tract. World J Gastroenterol 2017; 23(25): 4500-4507 Available from: URL: http://www.wjgnet.com/1007-9327/full/v23/i25/4500.htm DOI: http://dx.doi.org/10.3748/wjg.v23.i25.4500

INTRODUCTION

Before 1985, quisqualate was known to be an agonist of ionotropic receptors (AMPA, kainate), but, in that year, its ability to stimulate the synthesis of inositol phosphates in striatal neurons was also demonstrated[1]. Soon after, in 1986, Nicoletti et al[2] showed that glutamate stimulates polyphosphoinositide (PI) hydrolysis in hippocampal slice brains from newborn rats. These pioneering studies opened up the way for the discovery and identification of a new family of receptors, now called metabotropic glutamate receptors (mGluRs). The term metabotropic was adopted to distinguish them from ionotropic glutamate receptors.

The mGluR family belongs to Class C G-protein coupled receptors (GPCRs) and consists of eight different subtypes (mGluR1-8) classified into three groups on the basis of sequence similarities, intracellular signaling and pharmacological properties: Group I receptors (Subtypes mGluR1 and mGluR5); Group II receptors (Subtypes mGluR2 and mGluR3) and Group III receptors (Subtypes mGluR4, mGluR6, mGluR7 and mGlu8). Group I receptors are coupled to G<sub>i</sub> proteins and activate phospholipase C<sub>i</sub>, which in turn hydrolyzes phosphatidylinositol 4,5-bisphosphate to inositol trisphosphate (IP<sub>3</sub>) and diacylglycerol (Figure 1). This pathway leads to calcium release from endoplasmic reticulum and activation of numerous kinases, such as protein kinase A, protein kinase C, extracellular signal-related kinase (ERK) and mitogen-activated protein kinase (MAPK). On the contrary, Group II and Group III receptors are coupled to G<sub>q</sub> proteins, leading to the inhibition of cAMP synthesis[3]; these mGluRs act as regulators, providing negative feedback that inhibits glutamate release.

Like other mGluR subtypes, mGluR5s contain a phylogenetically conserved, extracellular orthosteric binding site and a more variable allosteric binding site, located on the heptahelical transmembrane domain. Given allosteric binding sites’ variability, subtype-selective allosteric modulators have been found and are frequently used in basic, preclinical and clinical research. A recent review, focused on mGluR5 localization, reported that this receptor is not restricted to postsynaptic membrane and extrasynaptic regions but is also found in intracellular membranes in many different brain regions such as inner nuclear, outer nuclear and endoplasmic reticulum membranes[4]. Numerous studies have also demonstrated the presence of mGluR5s in a number of peripheral non-neuronal cells. For instance, mGluR5s are found in insulin-containing vesicles purified from clonal pancreatic beta-cells[5], in rat and human testis[6] as well as in murine thymocytes and thymic stromal cells[7].

The present study reviews and discusses published data on the localization and role of mGluR5s in the gastrointestinal tract (GI) and accessory digestive organs such as the liver and pancreas. We used articles searched for in PubMed, MEDLINE, Google Scholar, and Google databases using the acronyms mGluR5 and mGlu5 in combination with mouth, esophagus, stomach, intestine, tongue, liver and pancreas to identify articles relating to mGluR5s in the GI published in the English-language literature from January 1985 to December 2016.

MGLUR5S IN THE GASTROINTESTINAL TRACT

mGluR5s in the mouth

The analysis of Group I mGluR localization in the mouth shows that mGluR5s, but not mGluR1s, are constitutively expressed in the trigeminal ganglion[8] and the masseter muscle[9]. During mandibular disorders
mGluR5s in the gastrointestinal tract

Figure 1 Schematic representation of metabotropic glutamate 5 receptor functions. DG: Diacylglycerol; ER: Endoplasmic reticulum; IP3: Inositol trisphosphate; PKC: Protein kinase C; PLC: Phospholipase C.

characterized by pain in the temporomandibular joint (TMJ), inflammation is associated with mGluR5 upregulation that differentially modulates the expression of glutamate receptors in male rats, suggesting that the use of mGluR5 antagonists may be effective in the control of inflammation pain conditions[10].

Some studies concerned with the orofacial area, highlight the role of peripheral Group I mGluRs in interleukin-1beta (IL-1beta)-induced mechanical allodynia: the results show that rat treatment with mGluR5 antagonists, Methyl-6-(phenylethynyl)pyridine (MPEP) or SIB1893, 10 min prior to injection of IL-1beta suppress IL-1beta-induced mechanical allodynia[11-13].

Using immunofluorescence, mGluR5s have also been identified in the terminal region of axon innervating human dental pulp suggesting their involvement in receptor-mediated inflammatory nociception. Odontoblasts also express mGluR5s and may contribute to the transduction of nociceptive signals[14].

mGluR1s and mGluR5s have been studied in oral cancer as the mGluR family is known to participate in tumorigenesis[15]: mGluR5 has been detected in oral squamous cell carcinoma (SCC) using both human cell cultures and tissue specimens[16]. Furthermore, in addition to cell membrane localization, mGluR5s were found in cytoplasm; by using a specific agonist (DPG) and antagonist (MPEP) the authors of this study concluded that these receptors may be involved in tumor progression and prognosis[16].

mGluR5s in the esophagus/stomach

The expression of mGluR5 has been found in gastroesophageal vagal pathways in ferret, dog and mouse models and is also involved in the peripheral excitatory modulation of vagal afferent mechanosensitivity input[17-19]. The use of the mGluR5 antagonist, MPEP, has highlighted a decrease in reflex events through inhibition of transient lower sphincter relaxation (TLESR) in rats and pigs; mGluR5 stimulation has also been found on enteric glia in the ileum and colon of mice, rats and pigs; mGluR5 stimulation increases c-Fos and pERK1/2 activation specifically in enteric glia, establishing that mGluR5s are expressed in these cells. In addition, in this study, mGluR5 expression was shown to be decreased during chronic inflammation

found in human tissues indicating a potential peripheral effect of mGluR5 modulators[21]. In a trial involving a small group of patients with gastroesophageal reflex disease (GERD), use of ADX10059 a mGluR5 negative allosteric modulator, was associated with an improvement in clinical symptoms characterized by reduced acid reflux[22]. The results of randomized clinical trials on the effects of mGluR5 blockers in patients with GERD have confirmed and supported the reduction in TLESR and reflux events[23-25]. The poor tolerability (dizziness and nausea) associated with the use of ADX10059, has been reduced using a modified-release formulation or mono-therapy[23,24]. However, ADX10059 did not show to be significantly effective in refractory GERD patients[26]; furthermore, in a study on migraine, high incidence of hepatic transaminase was observed[27]. This effect appears to be related specifically to ADX10059 and not to the mGluR5-inhibiting mechanism of action[27], since the use of single doses of AZD2066, a non-competitive antagonist of mGluR5, in a small group of healthy subjects, has reduced the number of postprandial reflux episodes and appears to be better tolerated[25]. However, these preliminary results deserve further confirmation[27].

mGluR5s in the intestine

The study of mGluRs in the enteric nervous system (ENS), which is unique in its ability to mediate reflex activity independently of the CNS, has demonstrated that the Group I mGluRs are present in the submucous plexus of guinea-pig ileum; mGluR5-immunoreactivity has been found to be located exclusively on submucous neurons with other types of cells devoid of staining. In general, the immunolabeling was cytoplasmic, filling the perikarya and occasionally proximal dendrites. In addition, the staining intensity of the cell bodies varied: some were heavily stained, others only lightly. Immunoreactivities for mGluR1 and mGluR5 were also found in submucous plexus neurons of the jejunum and colon[28]. Other findings have demonstrated that Group I mGluRs are present in the ENS supporting their role in enteric reflexes and suggesting that the observed internalization might be a major mechanism for regulation of mGluR activity[29].

Because enteric neurons, like their equivalents in the CNS, are intimately associated with glial cells, one study has been carried out to test for glial mGluR5 expression in various species and assess whether enteric glia express mGluR5s and, if so, whether mGluR5 expression changes during intestinal inflammation[30]. mGluR5 expression has also been found on enteric glia in the ileum and colon of mice, rats and pigs; mGluR5 stimulation increases c-Fos and pERK1/2 activation specifically in enteric glia, establishing that mGluR5s are expressed in these cells. In addition, in this study, mGluR5 expression was shown to be decreased during chronic inflammation

Figure 1 Schematic representation of metabotropic glutamate 5 receptor functions. DG: Diacylglycerol; ER: Endoplasmic reticulum; IP3: Inositol trisphosphate; PKC: Protein kinase C; PLC: Phospholipase C.
suggesting that mGluR5 signaling may be reduced in colitis\textsuperscript{30}; enteric glia can be considered a target of the glutamatergic neurotransmitter system in the ENS and that changes in mGluR5 expression may play a modulatory role in inflammation\textsuperscript{30}.

mGluRs are also involved in visceral pain: because mGluR5 antagonists inhibit colorectal distension (CRD)-evoked visceromotor (VMR) in rats, it has been concluded that mGluR5s participate in mediating mechanically evoked visceral nociception in the GI tract\textsuperscript{31}.

Recent evidence has demonstrated that in a model of total parenteral nutrition (TPN), glutamate supplementation prevents intestinal mucosal atrophy and a reduced epithelial barrier function (EBF) as compared with untreated animals\textsuperscript{32}. It has further been reported that mGluR5s are involved in the effects of glutamate on EBF as 3-[(2-Methyl-4-thiazolyl)ethynyl]pyridine (MTEP), an mGluR5 antagonist, alleviates the decreased EBF observed in TPN animals treated with glutamate\textsuperscript{32}.

**MGLUR5S IN ACCESSORY DIGESTIVE ORGANS**

**mGluR5s in the tongue**

Inflammatory tongue pain is a more recently identified area of involvement for mGluR5s; extracellular signal-regulated kinase signaling (pERK signaling) is involved in the development of mechanical and heat hypersensitivity that appears to evolve in the inflamed tongue\textsuperscript{33}.

Assessment of mGluR5 localization has also been carried out on oral tongue cancer cells: HSC3 cells exhibit mGluR5; the use of the agonist DHPG increased tumor cell migration, invasion, and adhesion; this event has been shown to be reversed by the mGluR5 antagonist MPEP\textsuperscript{34}. Similar findings - mGluR5 functions as an oncogene in solid cancers, including oral cancer - were found using B88 cells obtained from a patient with tongue cancer\textsuperscript{35}.

**mGluR5s in the liver**

The presence of mGluRs in the liver was first suggested by Sureda et al\textsuperscript{35}, who showed that the competitive agonists, quisqualate and ACPD, stimulated polyphosphoinositide hydrolysis in primary rat hepatocytes. In this work, 100 μmol/L quisqualate and 100 μmol/L ACPD significantly increased the formation of [3H]InsP\textsubscript{2} after 2 and 5 d of incubation, with respect to basal levels. This data suggested the activation of a Group I mGlu receptor, although at the time the subtype was not identified, since both quisqualate and ACPD were unspecific agonists. The presence of mGluR5s in rat hepatocytes was subsequently demonstrated for the first time by Storto et al\textsuperscript{36}, with mGluR5 protein and mRNA expression levels comparable to those observed in rat cerebral cortex. In this article, Storto et al\textsuperscript{36} show that ACPD and quisqualate worsen cell injury in hepatocytes exposed to anoxic conditions; on the contrary MPEP, the selective negative allosteric modulator of mGluR5, protects hepatocytes against necrosis, suggesting that the activation of mGluR5s by endogenous glutamate is involved in the development of hypoxic injury\textsuperscript{36}. In a subsequent study, Storto et al\textsuperscript{36}, demonstrated that the onset of hypoxic damage was significantly delayed in hepatocytes from mGlu5 receptor knockout mice, as well as in hepatocytes from wild type mice treated with 30 μmol/L MPEP. This study also observed substantial improvements in cell viability and intracellular free-radical production, with respect to wild type control hepatocytes\textsuperscript{37}.

It has been suggested that peripheral mGluRs could be activated by non-synaptic glutamate\textsuperscript{38}, probably synthesized from α-Ketoglutaric acid, a by-product of the Krebs cycle. During anoxia, blockade of the Krebs cycle causes accumulation of this intermediate, favoring its conversion into glutamate by various enzymes, such as glutamate dehydrogenase or aspartate transaminase\textsuperscript{39}. Furthermore, the release of toxic glutamate concentrations in the CNS, in hypoxic conditions, has been variously attributed to increased activity in the mitochondrial enzyme glutaminase\textsuperscript{40} or reduced activity of the ATP-dependent enzyme glutamine synthetase\textsuperscript{41}. Similarly, Storto et al\textsuperscript{36}, had previously demonstrated an increase in glutamate release in hypoxic conditions in isolated rat hepatocytes. Subsequently, Storto et al\textsuperscript{42} showed that the noncompetitive mGluR5 antagonists MPEP, SIB-1757 and SIB-1893 reduce ROS-induced toxicity in both *in vitro* and *in vivo* models. This study shows that selective blockade of mGluR5s reduce ROS production, malondialdehyde formation and thiol group oxidation, and improve hepatocyte viability in isolated hepatocytes treated with 0.5 mmol/L tert-butyldihydroperoxide. Furthermore, in mice treated with acetaminophen (300 mg/kg), MPEP protects against toxicity, reducing the formation of ROS, due to acetaminophen-induced GSH depletion. The mechanism responsible for the protection against acetaminophen has not been clearly elucidated. However, in liver homogenates, Western Blot analysis has shown a significant acetaminophen-induced increase in inducible nitric oxide synthase (iNOS) expression, markedly reduced in mice co-injected with MPEP (20 mg/kg). Storto et al\textsuperscript{42} also rules out the possibility of mGluR5 negative allosteric modulators (NAMs) providing protection through free-radical scavenging activity; somewhat curiously, MPEP maintains its beneficial effects even though it significantly depletes glutathione (GSH) in hepatocytes, whereas SIB-1893, another mGluR5...
selective NAM, structurally different from MPEP, shows similar effects without reducing GSH stores. Based on these observations, Storto et al[42] have posited an indirect, GSH-independent effect of MPEP against acetaminophen toxicity. Indeed, the formation of GSH conjugates with mGluR5 ligands containing an acetylene group, has recently been demonstrated[43]. Since MPEP, but not SIB-1893, contains an acetylene bond, MPEP probably forms GSH-conjugates, which, in retrospect, explains the MPEP-induced GSH depletion. This observation further supports the hypothesis that MPEP protection may well occur without any interference with the GSH-mediated tert-butylhydroperoxide metabolism, and cannot be entirely ascribed to reduced ROS formation[42]. Furthermore, Jesse et al[46] had found a decrease in liver injury and mortality in a hepatitis model induced by lipopolysaccharide and D-galactosamine using the same dose of MPEP reported by Storto et al[42]. Of note, this new study has reported a reduction in malondialdehyde formation and no changes in GSH-S-transferase after the administration of MPEP in agreement with the previous study by Storto et al[42].

Recently, hepatic mitochondrial dysfunctions have been observed in a rodent model of Parkinson disease. Rats with nigrostriatal degeneration induced by 6-hydroxydopamine intrastratal administration have lower mitochondrial membrane potential and higher ROS production, with respect to sham operated animals[45]. In the same model, the administration of MPEP reduces ROS and improves ATP production with respect to Parkinsonian rats not treated with MPEP. This supports the hypothesis that MPEP may reduce ROS indirectly by improving mitochondrial efficiency rather than through direct ROS scavenging action[46].

The effects of inhibiting mGluR5 activity in hepatocellular carcinoma (HCC) have been analyzed using hepatocarcinoma cell lines and a xenograft model. Inactivation of mGluR5s with MPEP has been shown to cause inhibition of cell growth, migration, and invasion of HepG2 and Bel-7402 cells. Moreover, inhibition of tumor growth and potential metastasis of HCC has also been found in nude mice. Furthermore, mGluR5-mediated extracellular signal-regulated kinase (ERK) phosphorylation has been shown to be partially involved in cell growth and migration, as found by stimulation of (S)-3,5-Dihydroxypheynylglycine (DHPG), an agonist of the mGluR5 and blockade of MPEP and U0126, an inhibitor of mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (MEK)[47].

**mGluR5s in the pancreas**

Using RT-PCR and immunoblotting analysis, one study has detected mGluR5s in rat and human islets of Langerhans whereas mGluR1s were not found[48]. The treatment of pancreatic beta cells, MIN6, with a specific Group 1 agonist DHPG, stimulates insulin release at low glucose concentrations (3-10 mmol/L). This, however, is absent in the presence of high concentrations of glucose (25 mmol/L). A subsequent study has demonstrated that anti-mGluR5 antibodies do not immunostain any islet cells, but do immunostain synaptic terminals and blood vessels in the pancreas[49].

Moving from these findings, Storto et al[50], have confirmed that beta-cells express mGluRs and have reported that these receptors are found not just in the cell surface but also in insulin-secreting granules. The endogenous activation of mGluR5s appears to be permissive to glucose-stimulate Ca\(^{2+}\) release and insulin secretion. The study showed that the use of mGluR5 agonists (L-glutamate, quisqualate or DHPG) act extracellularly involving no changes in Ca\(^{2+}\) concentration or insulin secretion in pancreatic beta-cells. On the contrary, treatment with MPEP, a highly lipophilic drug and selective antagonist of mGluR5, or the use of mice lacking mGluR5 showed a blunted insulin response to glucose[50]. Thus, drugs such as mGluR5 modulators, under development for neurologic and psychiatric disorders, may also affect glucose homeostasis.

**CONCLUSION**

The wide distribution of mGluRs in plants and animals, from invertebrates to primates, suggests that mGluRs represent a primitive signalling system. Some published reviews have summarized current knowledge on GluRs, including both ionotropic and metabotropic receptors, in peripheral tissues[50]. However, only a few articles have focused on metabotropic receptors in the peripheral organs[51]. The presence of mGluRs in peripheral organs supports efforts to redirect pharmacological studies originally directed to the CNS toward new targets in peripheral districts such as the GI tract. Furthermore, the identification of mGluRs in non-neuronal tissues may well be crucial for predicting potential adverse effects during the use of CNS-targeted mGluR therapies.

Due to the role of mGluR5s as critical mediators and potential therapeutic targets for the treatment of numerous CNS disorders, this review has underscored possible adverse drug reactions in the GI tract using mGluR5 modulators, attempting to draw attention to the distribution and potential role of mGluR5s in the GI tract and in accessory digestive organs, in particular, the liver and pancreas (Table 1). Hopefully, this will encourage researchers to provide additional information that identifies specific targets and innovative therapeutic approaches in the treatment of GI diseases.
Measurement/observation

Acetaminophen damage
Antagonists block tumor cell migration and invasion
Cancer
Mitochondrial membrane potential
Mechanical and heat hypersensitivity
Reduction in reflux
Epithelial barrier function
Insulin secretion
Mortality, Lipid peroxidation
Mechanical allodynia
Visceromotor (VMR)

REFERENCES

1 Sladecek F, Pin JP, Récaens M, Bockaert J, Weiss S. Glutamate stimulates inositol phosphate formation in striatal neurons. *Nature* 1985; 317: 717-719 [PMID: 2865680 DOI: 10.1038/317717a0]

2 Nicotelli F, Iadarola MJ, Wroblewski JT, Costa E. Excitatory amino acid recognition sites coupled with inositol phospholipid metabolism: developmental changes and interaction with alpha 1-adrenoceptors. *Proc Natl Acad Sci USA* 1986; 83: 1931-1935 [PMID: 2869493]

3 Nicotelli F, Bockaert J, Coll哽ringile GL, Conn PJ, Collingridge GL, Conn PJ, Ferraguti F, Nicoletti F, De Blasi A. Expression of metabotropic glutamate receptor ligands. *Mol Pharmacol* 2014; 86: 774-785 [PMID: 25326002 DOI: 10.1124/mol.114.094763]

4 Jong YJ, Sergin I, Purgert CA, O’Malley KL. Location-dependent signaling of the group I metabotropic glutamate receptor mGlu5. *Mol Pharmacol* 2011; 60: 1017-1041 [PMID: 21036182 DOI: 10.1162/neuropharm.m.1010.10.022]

5 Storto M, Capobianco L, Battaglia G, Molinario G, Gradini R, Rizzo B, Di Mambro A, Mitchell KJ, Bruno V, Vairetti MP, Rutter GA, Nicoletti F. Insulin secretion is controlled by mGlu5 metabotropic glutamate receptors. *Mol Pharmacol* 2006; 69: 1234-1241 [PMID: 16424079 DOI: 10.1124/mol.105.018390]

6 Storto M, Saillese M, Salvatore L, Poulet R, Condorelli DF, Dell’ Albani P, Marcelli MF, Romeo R, Piomboni P, Barone N, Nicoletti F, Nicoletti F, De Blasi A. Expression of metabotropic glutamate receptors in the rat and human testis. *J Endocrinol* 2001; 170: 71-78 [PMID: 11431139 DOI: 10.1677/joe.0.17000071]

7 Storto M, de Graziia U, Battaglia G, Felli MP, Maroder M, Gulino A, Ragona G, Nicoletti F, Soreaian I, Frati L, Calogero A. Expression of metabotropic glutamate receptors in murine thymocytes and thymic stromal cells. *J Neuroimmunol* 2000; 109: 112-120 [PMID: 10996213 DOI: 10.1016/S0165-5728(00)00269-1]

8 Lee J, Ro JY. Differential regulation of glutamate receptors in trigeminal ganglia following masseter muscle inflammation. *Neurosci Lett* 2007; 421: 91-95 [PMID: 17560028 DOI: 10.1016/j.neulet.2007.05.031]

9 Lee HJ, Choi HS, Ju JS, Bae YC, Kim SK, Yoon YW, Ahn DK. Peripherial mGluR5 antagonist attenuated cranialfacial muscle pain and inflammation but not mGluR1 antagonist in lightly anesthetized rats. *Brain Res Bull* 2006; 70: 378-385 [PMID: 17027773 DOI: 10.1016/j.brainresbull.2005.09.021]

10 Li B, Lu L, Tan X, Zhong M, Guo Y, Yi X. Peripheral metabotropic glutamate receptor subtype 5 contributes to inflammation-induced hypersensitivity of the rat temporomandibular joint. *J Mol Neurosci* 2013; 51: 710-718 [PMID: 23807708 DOI: 10.1007/s12031-013-0052-2]

11 Ahn DK, Kim KH, Jung CY, Choi HS, Lim EI, Yoon DH, Bae YC. Role of peripheral group I and II metabotropic glutamate receptors in IL-1beta-induced mechanical allodynia in the orofacial area of conscious rats. *Pain* 2005; 118: 53-60 [PMID: 16154694 DOI: 10.1016/j.pain.2005.07.017]

12 Jung CY, Choi HS, Ju JS, Park HS, Kwon TG, Bae YC, Ahn DK. Central metabotropic glutamate receptors differentially participate in interleukin-1beta-induced mechanical allodynia in the orofacial area of conscious rats. *J Pain* 2006; 7: 747-756 [PMID: 17018335 DOI: 10.1016/j.jpain.2006.03.007]

13 Jung CY, Lee SY, Choi HS, Lim EI, Lee MK, Yang GY, Han SR, Youn DH, Ahn DK. Participation of peripheral group I and II metabotropic glutamate receptors in the development or maintenance of IL-1beta-induced mechanical allodynia in the orofacial area of conscious rats. *Neurosci Lett* 2006; 409: 173-178 [PMID: 17030435 DOI: 10.1016/j.neulet.2006.09.043]

14 Kim YS, Kim YJ, Park SK, Cho YS, Kwon TG, Ahn DK, Kim SK, Yoshida A, Bae YC. Expression of metabotropic glutamate receptor mGluR5 in human dental pulp. *J Endod* 2009; 35: 690-694 [PMID: 19410844 DOI: 10.1016/j.joen.2009.02.005]

15 Li S, Huang S, Peng SB. Overexpression of G protein-coupled receptors in cancer cells: involvement in tumor progression. *Int J Oncol* 2005; 27: 1329-1339 [PMID: 16211229]

16 Park SY, Lee SA, Han IH, Yoo BC, Lee SH, Park YJ, Cha IH, Kim J, Choi SW. Clinical significance of metabotropic glutamate receptor 5 expression in oral squamous cell carcinoma. *Oncol Rep* 2007; 17: 81-87 [PMID: 17143482 DOI: 10.3892/ort.17.1.81]

17 Frishby CL, Mattsson JP, Jensen JM, Lehmann A, Dent J, Blackshaw LA. Inhibition of transient lower esophageal sphincter relaxation and gastroesophageal reflux by metabotropic glutamate receptor ligands. *Gastroenterology* 2005; 129: 995-1004 [PMID: 16143137 DOI: 10.1053/j.gastro.2005.06.069]
Expression of a functional metabotropic glutamate receptor 5 on neurons.}

Internalization of metabotropic glutamate receptor 5 in enteric guinea-pig ileum.}

Inhibitors (PPIs) in Patients With Gastroesophageal Reflux Disease.}

Symptoms in gastro-oesophageal reflux disease.}

Inhibitors (PPIs) in Patients With Gastroesophageal Reflux Disease: a self-perpetuating crosstalk?}

Impaired hepatic function and glutaminase following neuronal death.}

Production of extracellular glutamate by the mitochondrial glutamatergic neurons is less sensitive to hypoxic damage.}

Metabotropic glutamate receptors protects rat hepatocytes against hypoxic damage.}

Dx: S-577 [DOI: 10.1016/S0016-5085(11)62391-3]

Symptoms in gastro-oesophageal reflux disease.}

Glutaminase following neuronal death.}

Glutamate prevents intestinal atrophy via luminal nutrient sensing in a mouse model of total parenteral nutrition.}

Inflammatory tongue pain via extracellular signal-regulated kinase signaling in the trigeminal spinal subnucleus caudalis and upper cervical spinal cord. J Neuroinflammation 2012; 9: 258 [PMID: 23181395 DOI: 10.1186/1742-2044-9-258]

The effects of a novel metabotropic glutamate receptor 5 antagonist on the stromal cell-derived factor-1/CXCR4 system in an oral cancer. PLoS One 2013; 8: e80773 [PMID: 24236200 DOI: 10.1371/journal.pone.0080773]

The role of metabotropic glutamate receptor 5 in the regulation of synaptic transmission.}

The role of metabotropic glutamate receptors protects rat hepatocytes against hypoxic damage.}

Glutamate, glutamine and glutamate synthase in normal and cirrhotic human liver.}

Metabotropic glutamate receptor 5 antagonist G501-G511 [PMID: 17053158 DOI: 10.1152/jn.00353.2006]

A proof-of-concept study evaluating the effect of ADX10059, a metabotropic glutamate receptor 5 antagonist, on the stromal cell-derived factor-1/CXCR4 system in an oral cancer. PLoS One 2013; 8: e80773 [PMID: 24236200 DOI: 10.1371/journal.pone.0080773]

Glutamate prevents intestinal atrophy via luminal nutrient sensing in a mouse model of total parenteral nutrition.}

Metabotropic glutamate receptor 5 antagonist (AZD2066) on transient lower oesophageal sphincter relaxations and reflux episodes in patients with gastro-oesophageal reflux disease.}

Stomatolog 2012; 35: 1231-1242 [PMID: 22469098 DOI: 10.3390/s09010037]

Randomised clinical trial: effects of monotherapy with ADX10059, a mGluR5 inhibitor, on symptoms and reflux events in patients with gastro-oesophageal reflux disease.}

Aliment Pharmacol Ther 2011; 33: 911-921 [PMID: 21320138 DOI: 10.1111/j.1365-2636.2011.04596.x]

The effects of a novel metabotropic glutamate receptor 5 antagonist 859-872 [PMID: 17405149 DOI: 10.1002/glia.20507]

involvement of metabotropic glutamate receptor 5 in visceral pain.}

2003; 29: 323-329 [PMID: 19153979 DOI: 10.1002/jat.1413]

Flavell A, Varetti M, Ambrosi G, Rizzo V, Richelmi P, Blandini F, Armentero MT. Impaired hepatic function and central dopaminergic denervation in a rodent model of Parkinson’s disease: a self-perpetuating crosstalk? Biochim Biophys Acta 2012; 1822: 176-184 [PMID: 22119596]

Ferrigno A, Varetti M, Ambrosi G, Rizzo V, Richelmi P, Blandini F, Fuzzati-Armentero MT. Selective blockade of mGlur5 metabotropic glutamate receptors is protective against hepatic mitochondrial dysfunction in 6-OHDA lesioned Parkinsonian rats.}
Wu YL, Wang NN, Gu L, Yang HM, Xia N, Zhang H. The suppressive effect of metabotropic glutamate receptor 5 (mGlu5) inhibition on hepatocarcinogenesis. Biochimie 2012; 94: 2366-2375 [PMID: 22706282 DOI: 10.1016/j.biochi.2012.06.006]

Brice NL, Varadi A, Ashcroft SJH, Molnar E. Metabotropic glutamate and GABAB receptors contribute to the modulation of glucose-stimulated insulin secretion in pancreatic beta cells. Diabetologia 2002; 45: 242-252 [DOI: 10.1007/s00125-001-0750-0]

Uehara S, Muroyama A, Echigo N, Morimoto R, Otsuka M, Yatsushiro S, Moriyama Y. Metabotropic glutamate receptor type 4 is involved in autoinhibitory cascade for glucagon secretion by alpha-cells of islet of Langerhans. Diabetes 2004; 53: 998-1006 [PMID: 15047615]

Gill SS, Pulido OM. Glutamate receptors in peripheral tissues: current knowledge, future research, and implications for toxicology. Toxicol Pathol 2001; 29: 208-223 [PMID: 11421488]

Julio-Pieper M, Flor PJ, Dinan TG, Cryan JF. Exciting times beyond the brain: metabotropic glutamate receptors in peripheral and non-neural tissues. Pharmacol Rev 2011; 63: 35-58 [PMID: 21228260 DOI: 10.1124/pr.110.004036]

Ferrigno A et al. mGluR5 in the gastrointestinal tract
